In a just published perspective piece in The New England Journal of Medicine, U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb, M.D. outlines with colleagues the multi-prong approach the agency is using to combat the complex issue that is misuse and abuse of opioids while detailing surveillance measures already underway to detect rapidly the next wave of drug abuse. Among this so-called proactive pharmacovigilance plan is employing a social media “listening platform” that monitors opioid conversation traffic in traditional and other sites or forums that are publicly available. When alternative substances are mentioned, the data mining deepens.
[For more of this story, written by Jamie Wells, go to https://www.acsh.org/news/2018...-follows-pills-13035]
Comments (1)